AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa
AM-Pharma Announces Positive Clinical Data From Phase 1b Study Evaluating Ilofotase Alfa in Hypophosphatasia Patients
After failing in a phase 3 study for a severe kidney complication of sepsis, AM-Pharma is redirecting its lead program to a different kind of kidney damage. Along with the revised clinical development strategy, the Dutch biotech is cutting staff and getting a new CEO.
AM-Pharma Announces Updated Clinical Development Strategy
AM-Pharma to Present Data From Phase 3 REVIVAL Study at Upcoming Scientific Conferences
Pfizer may have dodged a bullet by walking away from AM-Pharma. The biotech, a onetime takeover target for the Big Pharma, has stopped a phase 3 clinical trial of its kidney injury candidate early after it failed an interim futility analysis.
UTRECHT, Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating that ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury (AKI) has been published in the journal, Frontiers in Medicine-Nephrology. The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI. The publication is available now online at https://www.frontiersin.org/articles/10.3389/fmed.2022.931293/abstract.
UTRECHT, Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th, 2022 at 8:00 AM ET.
UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, are scheduled to participate in SVB Leerink’s Biopharma Private Company Connect on Tuesday, March 29th, 2022. The company will be taking investor meetings at the conference, which can be requested through SVB Leerink.
SAN DIEGO & UTRECHT, Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced two presentations at the 27th International Conference on Advances in Critical Care Nephrology in San Diego, CA. In the oral presentation at 11:30 a.m. on Thursday, March 10, 2022, Dr. Peter Pickkers, Professor of Experimental Intensive Care Medicine at Radboud University Nijmegen Medical Center, will provide an overview of AM-Pharma’s ongoing Phase 3 REVIVAL study. The second presentation is a poster with new data supporting the importance of managing acute kidney injury (AKI) in patients undergoing cardiac surgery, which will be presented today.